Telik, Inc.
Records under this name other than patents Telik, Inc. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 6,506,739 | Bis-(N,N'-bis-(2-haloethyl)amino)phosphoramidates as antitumor agents Term ended Term ended May 1, 2021 · From the USPTO record | Term ended | Term ended May 1, 2021 | From the USPTO record |
| US 8,334,266 | Process for and intermediates in the preparation of canfosfamide and its salts Formerly held Lapsed on the fee record Ended Dec 18, 2020 · From the USPTO record | Lapsed on the fee record | Ended Dec 18, 2020 | From the USPTO record |
| US 8,093,231 | Sulfonylethyl phosphorodiamidates Lapsed on the fee record Ended Jan 10, 2020 · From the USPTO record | Lapsed on the fee record | Ended Jan 10, 2020 | From the USPTO record |
| US 6,337,338 | Heteroaryl-aryl ureas as IGF-1 receptor antagonists Formerly held Term ended Term ended Dec 15, 2019 · From the USPTO record | Term ended | Term ended Dec 15, 2019 | From the USPTO record |
| US 6,054,286 | Methods to identify immunomodulators using cognate interaction of PKC-theta Formerly held Term ended Term ended Jan 15, 2019 · From the USPTO record | Term ended | Term ended Jan 15, 2019 | From the USPTO record |
| US 8,841,476 | Preparation of crystalline ezatiostat hydrochloride ansolvate form D Lapsed on the fee record Ended Sep 23, 2018 · From the USPTO record | Lapsed on the fee record | Ended Sep 23, 2018 | From the USPTO record |
| US 8,759,303 | Compositions and methods for treating myelodysplastic syndrome Lapsed on the fee record Ended Jun 24, 2018 · From the USPTO record | Lapsed on the fee record | Ended Jun 24, 2018 | From the USPTO record |
| US 8,716,521 | Formulations of canfosfamide and their preparation Lapsed on the fee record Ended May 6, 2018 · From the USPTO record | Lapsed on the fee record | Ended May 6, 2018 | From the USPTO record |
| US 7,029,695 | Therapeutic compositions containing glutathione analogs Lapsed on the fee record Ended Apr 18, 2018 · From the USPTO record | Lapsed on the fee record | Ended Apr 18, 2018 | From the USPTO record |
| US 6,992,086 | Antagonists of MCP-1 function and methods of use thereof Lapsed on the fee record Ended Jan 31, 2018 · From the USPTO record | Lapsed on the fee record | Ended Jan 31, 2018 | From the USPTO record |